Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Targeting the Mycobacterium ulcerans cytochrome bc1:aa3 for the treatment of Buruli ulcer.

Scherr N, Bieri R, Thomas SS, Chauffour A, Kalia NP, Schneide P, Ruf MT, Lamelas A, Manimekalai MSS, Grüber G, Ishii N, Suzuki K, Tanner M, Moraski GC, Miller MJ, Witschel M, Jarlier V, Pluschke G, Pethe K.

Nat Commun. 2018 Dec 18;9(1):5370. doi: 10.1038/s41467-018-07804-8.

2.

Prospective study on antimicrobial resistance in leprosy cases diagnosed in France from 2001 to 2015.

Chauffour A, Lecorche E, Reibel F, Mougari F, Raskine L, Aubry A, Jarlier V, Cambau E; CNR-MyRMA.

Clin Microbiol Infect. 2018 Nov;24(11):1213.e5-1213.e8. doi: 10.1016/j.cmi.2018.06.004. Epub 2018 Jun 12.

3.

Are moxifloxacin and levofloxacin equally effective to treat XDR tuberculosis?

Maitre T, Petitjean G, Chauffour A, Bernard C, El Helali N, Jarlier V, Reibel F, Chavanet P, Aubry A, Veziris N.

J Antimicrob Chemother. 2017 Aug 1;72(8):2326-2333. doi: 10.1093/jac/dkx150.

PMID:
28535203
4.

Sterilizing Activity of Fully Oral Intermittent Regimens against Mycobacterium Ulcerans Infection in Mice.

Chauffour A, Robert J, Veziris N, Aubry A, Jarlier V.

PLoS Negl Trop Dis. 2016 Oct 18;10(10):e0005066. doi: 10.1371/journal.pntd.0005066. eCollection 2016 Oct.

5.

In vivo Mycobacterium tuberculosis fluoroquinolone resistance emergence: a complex phenomenon poorly detected by current diagnostic tests.

Bernard C, Aubry A, Chauffour A, Brossier F, Robert J, Veziris N.

J Antimicrob Chemother. 2016 Dec;71(12):3465-3472. Epub 2016 Sep 7.

PMID:
27605600
6.

New Insights into the Geographic Distribution of Mycobacterium leprae SNP Genotypes Determined for Isolates from Leprosy Cases Diagnosed in Metropolitan France and French Territories.

Reibel F, Chauffour A, Brossier F, Jarlier V, Cambau E, Aubry A.

PLoS Negl Trop Dis. 2015 Oct 6;9(10):e0004141. doi: 10.1371/journal.pntd.0004141. eCollection 2015.

7.

Aedesin: structure and antimicrobial activity against multidrug resistant bacterial strains.

Godreuil S, Leban N, Padilla A, Hamel R, Luplertlop N, Chauffour A, Vittecoq M, Hoh F, Thomas F, Sougakoff W, Lionne C, Yssel H, Missé D.

PLoS One. 2014 Aug 27;9(8):e105441. doi: 10.1371/journal.pone.0105441. eCollection 2014.

8.

Resistance of M. leprae to quinolones: a question of relativity?

Veziris N, Chauffour A, Escolano S, Henquet S, Matsuoka M, Jarlier V, Aubry A.

PLoS Negl Trop Dis. 2013 Nov 14;7(11):e2559. doi: 10.1371/journal.pntd.0002559. eCollection 2013 Nov.

9.

Impact of fluoroquinolone resistance on bactericidal and sterilizing activity of a moxifloxacin-containing regimen in murine tuberculosis.

Fillion A, Aubry A, Brossier F, Chauffour A, Jarlier V, Veziris N.

Antimicrob Agents Chemother. 2013 Sep;57(9):4496-500. doi: 10.1128/AAC.00506-13. Epub 2013 Jul 8.

10.

Chemotherapy-associated changes of histopathological features of Mycobacterium ulcerans lesions in a Buruli ulcer mouse model.

Ruf MT, Schütte D, Chauffour A, Jarlier V, Ji B, Pluschke G.

Antimicrob Agents Chemother. 2012 Feb;56(2):687-96. doi: 10.1128/AAC.05543-11. Epub 2011 Dec 5.

11.

Should moxifloxacin be used for the treatment of extensively drug-resistant tuberculosis? An answer from a murine model.

Poissy J, Aubry A, Fernandez C, Lott MC, Chauffour A, Jarlier V, Farinotti R, Veziris N.

Antimicrob Agents Chemother. 2010 Nov;54(11):4765-71. doi: 10.1128/AAC.00968-10. Epub 2010 Aug 30.

12.

Impacts of dosing frequency of the combination rifampin-streptomycin on its bactericidal and sterilizing activities against Mycobacterium ulcerans in mice.

Ji B, Chauffour A, Aubry A, Robert J, Ibrahim M, Jarlier V.

Antimicrob Agents Chemother. 2009 Jul;53(7):2955-9. doi: 10.1128/AAC.00011-09. Epub 2009 Apr 13.

13.

A once-weekly R207910-containing regimen exceeds activity of the standard daily regimen in murine tuberculosis.

Veziris N, Ibrahim M, Lounis N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V.

Am J Respir Crit Care Med. 2009 Jan 1;179(1):75-9. doi: 10.1164/rccm.200711-1736OC. Epub 2008 Oct 23.

PMID:
18948422
14.

Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice.

Ji B, Chauffour A, Robert J, Jarlier V.

Antimicrob Agents Chemother. 2008 Jun;52(6):1912-6. doi: 10.1128/AAC.00193-08. Epub 2008 Apr 7.

15.

Orally administered combined regimens for treatment of Mycobacterium ulcerans infection in mice.

Ji B, Chauffour A, Robert J, Lefrançois S, Jarlier V.

Antimicrob Agents Chemother. 2007 Oct;51(10):3737-9. Epub 2007 Jul 30.

16.

Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis.

Ibrahim M, Andries K, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V, Veziris N.

Antimicrob Agents Chemother. 2007 Mar;51(3):1011-5. Epub 2006 Dec 18.

17.

Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin.

Lefrançois S, Robert J, Chauffour A, Ji B, Jarlier V.

Antimicrob Agents Chemother. 2007 Feb;51(2):645-50. Epub 2006 Nov 13.

18.

Combinations of R207910 with drugs used to treat multidrug-resistant tuberculosis have the potential to shorten treatment duration.

Lounis N, Veziris N, Chauffour A, Truffot-Pernot C, Andries K, Jarlier V.

Antimicrob Agents Chemother. 2006 Nov;50(11):3543-7. Epub 2006 Sep 5.

19.

Genetic basis for natural and acquired resistance to the diarylquinoline R207910 in mycobacteria.

Petrella S, Cambau E, Chauffour A, Andries K, Jarlier V, Sougakoff W.

Antimicrob Agents Chemother. 2006 Aug;50(8):2853-6.

20.

In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans.

Ji B, Lefrançois S, Robert J, Chauffour A, Truffot C, Jarlier V.

Antimicrob Agents Chemother. 2006 Jun;50(6):1921-6.

21.

Bactericidal activities of R207910 and other newer antimicrobial agents against Mycobacterium leprae in mice.

Ji B, Chauffour A, Andries K, Jarlier V.

Antimicrob Agents Chemother. 2006 Apr;50(4):1558-60.

22.

Dihydropteroate synthase mutations in the folP1 gene predict dapsone resistance in relapsed cases of leprosy.

Cambau E, Carthagena L, Chauffour A, Ji B, Jarlier V.

Clin Infect Dis. 2006 Jan 15;42(2):238-41. Epub 2005 Dec 12.

PMID:
16355335
23.

Efficient intermittent rifapentine-moxifloxacin-containing short-course regimen for treatment of tuberculosis in mice.

Veziris N, Lounis N, Chauffour A, Truffot-Pernot C, Jarlier V.

Antimicrob Agents Chemother. 2005 Oct;49(10):4015-9.

Supplemental Content

Loading ...
Support Center